GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Current Deferred Revenue

IMGT (XKRX:456570) Current Deferred Revenue : ₩0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is IMGT Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

IMGT's current deferred revenue for the quarter that ended in Dec. 2023 was ₩0.00 Mil.

IMGT Current Deferred Revenue Historical Data

The historical data trend for IMGT's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Current Deferred Revenue Chart

IMGT Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - -

IMGT Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue - - - -

IMGT Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of IMGT's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IMGT (XKRX:456570) Business Description

Traded in Other Exchanges
N/A
Address
172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605
IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT (XKRX:456570) Headlines

No Headlines